Glycine modulators in schizophrenia.
N-methyl-D-aspartate (NMDA) receptor dysfunction may play a key role in the pathophysiology of schizophrenia. Recent studies have investigated the ability of NMDA/glycine-site modulators to ameliorate persistent negative and cognitive symptoms. Several full or partial glycine-site agonists, including glycine, D-serine and D-cycloserine, have shown effectiveness in small-scale clinical trials. Glycine levels in brain are regulated by GLYT1-type glycine transporters. Recently developed glycine transport inhibitors (GTI) have preclinical behavioral effects similar to those of glycine or D-serine, and may represent a 'next generation' approach to the treatment of the persistent negative and cognitive symptoms of schizophrenia.
Javitt
Daniel C
DC
Nathan Kline Institute for Psychiatric Research, New York University School of Medicine, Orangeburg 10962, USA. Javitt@nid.rfmh.org
D000818:Animals; D005998:Glycine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D018009:Receptors, Glycine / Q000819:agonists*; D016194:Receptors, N-Methyl-D-Aspartate / Q000819:agonists; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism*
D018009:Receptors, Glycine; D016194:Receptors, N-Methyl-D-Aspartate; C435781:org 24598; D005998:Glycine